Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics Q2 revenue falls 2% to $783.3 million; net income rises 8%

Mixed Impact 3 of 5 earnings Written later

United Therapeutics reported second quarter 2026 results for the period ended June 30, 2026. Total revenues fell 2% to $783.3 million, while net income rose 8% to $333.0 million and diluted earnings per share rose 13% to $7.27, helped by a lower income tax expense and a lower share count.

Key points

  • Total revenues were $783.3 million, down from $798.6 million in the second quarter of 2025.
  • Nebulized Tyvaso revenue fell 18% to $126.0 million, while Tyvaso DPI revenue rose 4% to $326.6 million.
  • Net income was $333.0 million, or $7.27 per diluted share, versus $309.5 million, or $6.41 per diluted share, a year earlier.
  • As of June 30, 2026, $500 million remained under the share repurchase program, which expires March 9, 2027.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECAug 5, 2026, 6:33 AM ET
Accession number0001082554-26-000028

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.